Skip to main content

NCT00095134 - A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy


CSR Summary

Not Yet Available


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Risperidone
Product Name
RISPERDAL®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
463
% Female
73.5%
% White
76.5%
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
RIS-DEP-401
Data Partner
Johnson & Johnson
Condition Studied
Depressive Disorder, Major
Mean/Median Age (Years)
46.0

Supporting Documentation

Clinical Study Report
Collected Datasets
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.